“Complete clearance is probably more than what most patients need to feel much better,” Werth said.
She explained that an approximately 50% improvement in the Cutaneous Lupus Erythematosus Disease Area and Severity Index activity score (CLASI-A) can represent meaningful benefit. Patients can experience less redness and scaling even when they do not reach clear or almost clear skin. Research has linked reductions in CLASI-A with meaningful improvements in patient-reported quality of life.4
“Quality of life can improve dramatically, even if you do not achieve clear or almost clear skin,” she said.
This distinction matters when discussing treatment expectations. A clearance endpoint captures one aspect of response; residual lesions do not necessarily mean a patient has experienced little benefit.
Why Response Timing Matters
Participants who switched from placebo to litifilimab at week 24 showed improvement as early as 4 weeks after starting treatment. Werth contrasted that timing with hydroxychloroquine, which she said takes approximately 2 months to begin working.1
During that interval, active discoid lupus can continue causing scarring, including permanent hair loss. Werth also noted that uncontrolled disease can produce pigmentary changes.
“An early response is very important to improve outcomes over time for these patients,” she said.
The AMETHYST findings do not establish that litifilimab prevents scarring or permanent hair loss. They describe changes in disease activity, leaving prevention of irreversible damage as an important question for future evaluation.
Pharmacist Reassessment and Remaining Questions
For pharmacists hearing that hydroxychloroquine is not working, Werth emphasized whether skin inflammation has begun improving.
“If somebody is not responding to hydroxychloroquine—if they are not starting to improve with less erythema and less scale within 2 months—it is really important to make sure the diagnosis is correct,” she said.
Her recommendation supports timely communication with the treating clinician, rather than prolonged acceptance of uncontrolled symptoms. She encouraged specialist referral when the clinician managing the patient is uncomfortable escalating treatment.
Safety also requires continued evaluation. During AMETHYST’s initial 24 weeks, adverse events occurred in 74.6% of litifilimab recipients and 64.7% of placebo recipients; serious adverse events occurred in 6.8% and 2.9%, respectively. The extended period identified no new safety signals, with serious adverse events reported in 3.4% of participants.1,3
Because all participants received active treatment after week 24, later findings offer information about sustained response but lack a concurrent placebo comparison. Phase 3 results are expected in the first half of 2027.1,3
If those findings support approval, Werth envisions an early role for patients with severe disease at risk of permanent disfigurement. For pharmacists, the immediate opportunity is recognizing persistent inflammation and helping patients obtain reassessment before further damage accumulates.
